H-WLSLLVPFV^-OH

Ref. 3D-PP41137

Informations sur le produit

• Nom: H-WLSLLVPFV^-OH

Description

Peptide H-WLSLLVPFV^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-WLSLLVPFV^-OH include the following: DCs pulsed with novel HLA-A2-restricted CTL epitopes against hepatitis C virus induced a broadly reactive anti-HCV-specific T lymphocyte response Z Guo, H Zhang, H Rao, D Jiang, X Cong, B Feng - PLoS , 2012 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0038390 HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. R Nayersina, P Fowler, S Guilhot, G Missale - (Baltimore, Md.: 1950 , 1993 - journals.aai.orghttps://journals.aai.org/jimmunol/article-abstract/150/10/4659/25949 Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA MJ Roy, MS Wu, LJ Barr, JT Fuller, LG Tussey - Vaccine, 2000 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X00003029 Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro MC Gagliardi, GD Petrillo, S Salemi - International , 1995 - academic.oup.comhttps://academic.oup.com/intimm/article-abstract/7/11/1741/666015 P73. Functional characterisation of HBV-specific T cell receptors for redirection of T cells against HBV infected hepatocytes K Krebs, K Metzger, L Weigand, C Dargel - for ImmunoTherapy of , 2014 - Springerhttps://link.springer.com/article/10.1186/2051-1426-2-S2-P47 End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB D Huang, D Wu, P Wang, Y Wang, W Yuan, D Hu - Journal of , 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0168827822000666 Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results CD Palmer , AR Rappaport, MJ Davis , MG Hart - Nature medicine, 2022 - nature.comhttps://www.nature.com/articles/s41591-022-01937-6 Comment on 'End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB' A Bertoletti , N Le Bert , AT Tan , C Boni - Journal of , 2023 - journal-of-hepatology.euhttps://www.journal-of-hepatology.eu/article/S0168-8278(23)00408-7/abstract

• Marque: Biosynth